ArticleCureus2025
Treatment-Resistant Atopic Dermatitis in Adulthood: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a chronic and relapsing skin condition that often begins in childhood but can persist or worsen into adulthood, significantly impacting quality of life. We present the case of a 41-year-old woman with long-standing, treatment-resistant AD, unresponsive to various systemic therapies including corticosteroids, methotrexate, thalidomide, and cyclosporine. Despite some control with methotrexate, she experienced frequent flares and side effects. This report highlights the clinical challenges and therapeutic considerations in managing chronic, treatment-resistant AD. It also shows the potential of targeted biologic therapies as more effective and better-tolerated alternatives. Early recognition of treatment resistance is crucial to improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.